恩夫韦肽

Description

Enfuvirtide · CAS 159519-65-0 · C204H301N51O64. UNII 19OWO1T3ZE. Hydrophobicity: -0.875.

Identification

CAS Registry Number	159519-65-0
PubChem CID	16130199
Molecular formula	C204H301N51O64
UNII (FDA)	19OWO1T3ZE

Computed Descriptors

Molecular Weight	4492
XLogP3	-14.7
Hydrogen Bond Donor Count	63
Hydrogen Bond Acceptor Count	67
Rotatable Bond Count	151
Exact Mass	4491.1933541
Monoisotopic Mass	4489.1866445
Topological Polar Surface Area	1900
Heavy Atom Count	319
Formal Charge	0

Physical & Chemical Properties

Hydrophobicity	-0.875

Physical description & handling notes

• White to off white amorphous solid
• Negligible solubility in pure water. In buffer pH 7.5, 85-142 mg/100 mL.
• Reconstituted solution should be stored under refrigeration at 2 to 8 °C (36 to 46 °F) and used within 24 hours.
• pKa = 4.25 (Glutamic acid side chains 5 in sequence); pKa = 10.5 (Lysine amino side chain 2 in sequence); pKa = 3.86 (Aspartic acid side chain 1 in sequence); pKa = 6.00 (Histidine side chain 1 in sequence)
• Parenteral: For injection: 108 mg Fuzeon (with sterile water for injection diluent), (Roche).

GHS Hazard Classification

Reported hazard statements	H317 (100%)

Documented Uses

• Preparation ... D.P. Bolognesi et al, WO 94 28920; eidem, US 5464933 (1994, 1995 both to Duke University)
• Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS.
• Enfuvirtide is an HIV fusion inhibitor, the first of this class of agents active against the human immunodeficiency virus (HIV). Enfuvirtide has not been associated with serum aminotransferase elevations during therapy or episodes of acute, clinically apparent liver injury.
• Breast Feeding; Lactation; Milk, Human; Anti-Infective Agents; Antiviral Agents; Anti-HIV Agents; Anti-Retroviral Agents; HIV Fusion Inhibitors
• Subcutaneous injection of enfuvirtide has been associated with reactions at the site of administration, including mild to moderate pain/discomfort, induration, erythema, presence of nodules or cysts, pruritus, and ecchymosis, in up to 98% of patients. In clinical studies, injection site reactions occurred during the first week of therapy in 86% of patients; in most patients, the severity of these reactions did not change during the 24-week study. Individual injection site reactions persisted for longer than 7 days
• For more Drug Warnings (Complete) data for ENFUVIRTIDE (10 total), please visit the HSDB record page.

Synonyms

Enfuvirtide; Pentafuside; Fuzeon; DP178; DP-178; Enfuvirtida; CHEBI:608828; Fuzeon T-20; 19OWO1T3ZE; DTXSID20166672; peptide T20; T20, Peptide; enfuvirtidum; RefChem:55093; DTXCID8089163; J05AX07

Frequently Asked Questions

What are the CAS number and molecular formula of Enfuvirtide?

CAS 159519-65-0; molecular formula C204H301N51O64; molecular weight — g/mol.

What other names is Enfuvirtide known by?

Enfuvirtide, Pentafuside, Fuzeon, DP178, DP-178, Enfuvirtida.

Is Enfuvirtide classified as hazardous?

Hazard statements reported: H317.

What are the key physical properties of Enfuvirtide?

Hydrophobicity: -0.875.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.